Catalyst Pharmaceuticals Inc (CPRX)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	413,545	379,068	358,171	347,747	337,178	301,040	260,098	218,031	179,810	161,209	144,274	130,624	118,949	114,133	108,927	102,572	102,034	101,613	102,685	101,796
Revenue (ttm)	US$ in thousands	491,734	460,482	434,475	411,347	398,204	348,393	302,949	256,480	214,203	191,755	170,465	153,717	140,833	133,539	126,902	120,142	119,073	118,181	119,761	118,994
Gross profit margin		84.10%	82.32%	82.44%	84.54%	84.67%	86.41%	85.86%	85.01%	83.94%	84.07%	84.64%	84.98%	84.46%	85.47%	85.84%	85.38%	85.69%	85.98%	85.74%	85.55%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $413,545K ÷ $491,734K
= 84.10%

The gross profit margin of Catalyst Pharmaceuticals Inc has shown some fluctuations over the past few years. It remained relatively stable around the mid-80% range from March 31, 2020, to March 31, 2023, indicating that the company was able to effectively manage its production costs and generate a healthy gross profit relative to its revenue during this period. However, there was a slight decline in the gross profit margin in the following quarters, dropping to 82.44% by June 30, 2024. This decline may suggest potential challenges in managing production costs or pricing strategies that could impact the company's profitability. Overall, while the gross profit margin has shown some variability, it still remains relatively high, indicating that Catalyst Pharmaceuticals Inc has been able to maintain strong profitability in its operations.